[1]. Raymon H, Grogan E, Mitmaker J, Orlo H, Clark. The evolution of biomarkers in thyroid cancer form mass screening to a personalized Biosig nature. Cancers. 2010; 2: 885-912. doi: 10, 3390/ cancers 2020885.
[2]. Wartofsky L. Increasing world incidence of thyroid cancer: Increased detection or higher radiation exposure? Hormones. 2010; 9(2): 103-108.
[3]. Larijani B, Aghakhani S, Haghpanah V. Review of thyroid cancer in Iran. Austral - Asian Journal of Cancer. 2005; 4(4): 199-203.
[4]. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clinical Oncology. 2010; 22: 395-404.
[5]. Kilfoy BA, Zheng T, Holford TR et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009; 20: 525-531.
[6]. Mohammad Khanlou Z, Pouladi N, Hosseinpour Feizi M, Pedram N. Lack of associations of the MDM4 rs4245739 polymorphism with risk of thyroid cancer among Iranian-Azeri patients: a case-control study. Asian Pac J Cancer Prev. 2017; 18(4): 1133-1138.
[7]. Varley JM. Germline TP53 mulations and li- fraumeni syndrom Human. Mutation. 2003; 21: 313-320.
[8]. Stegh AH. Targeting the p53 signaling pathway in cancer therapy- The promises, challenges, and perils. Expert Opin Ther Targets. 2012; 16(1): 67-83.
[9]. Lorne J, Hofseth S, Hussain P, Curtis C. Ha. p53: 25 years after its discovery. TRENDS in Pharmacological. Sciences. 2004; 25(4): 177-181.
[10].Ferraiuolo M, Verduci L, Blandino G, Strano S. Mutant p53 protein and the hippo transducers YAP and TAZ: a critical oncogenic node in human cancers. Int J Mol Sci. 2017; 18(5): 1-29.
[11].Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C, Di Cristofano A. Thyrocyte-specific inactivation of P53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget. 2011; 2(12): 1109-26.
[12].Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene P53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. The Journal of Clinical Investigation. 1993; 91(4): 1753-60.
[13].Khani H, Hosseinpourefeizi M, Pouladi N, Chaparzadeh N, Montazeri V, Azarfam. Detection of P53 gene exons 5 and 6 mutations among East Azerbaijani women with breast cancer. ZUMS Journal. 2011; 20(78): 36-46.
[14].Pouladi N, Hosseinpourfeizi MA, Khani H. Evaluation of mutations in exons 7 and 8 of TP53 gene in breast cancer patients from Azarbaijan. J Babol Univ Med Sci. 2016; 18(2):19-25
[15].Dehghan R, Hosseinpour Feizi MA, Pouladi N, Babaei E, Montazeri V, Fakhrjoo A, Sedaei A, Azarfam P, Nemati M. Association of P53 (-16ins-Pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Pathol Oncol Res. 2014 Nov 20.
[16].Hossein Pour Feizi M, Ravanbakhsh Gavgani R, Pourahmad R, Pouladi N, Azarfam P, Montazeri V. Association of p53 Arg/Pro polymorphism at codon 72 with risk of breast cancer in East Azerbaijani women. J Babol Univ Med Sci. 2012; 14(2): 31-8. [in Persian]
[17].http://www.umd.be:2072/4DACTION/OPMA4R/1. Available from Jun 2012.
[18].p53 knowledge base. Retrieved from http://p53.bii.a-star.edu.sg/aboutp53/snps/index.php.
[19].Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7): 1073-81 Available at: http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html [Accessed 14 Oct. 2016].
[20].Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. Nat methods. 2010; 7(4): 248-249. Available at: http://genetics.bwh.harvard.edu/pph2/ [Accessed 14 Oct. 2016].
[21].Berggren P, Hemminki K, Steineck G. p53 intron 7 polymorphisms in urinary bladder cancer patients and controls. Stockholm Bladder Cancer Group. Mutagenesis. 2000; 15(1): 57-60.
[22].Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004; 279(1): 348-55. Epub 2003 Oct 13.
[23].Kato SL, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14): 8424-9. Epub 2003 Jun 25.
[24].Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med. 2006; 9(3): 156-62.
[25].Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6): 622-629.
[26].Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015; 6: e1826.
[27].Tan BS, Tiong KH, Choo HL et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. Jul. 2015; 16(6): e1826.
[28].Sadeghi M, Motovali Bashi M, Hojati Z. Association of a polymorphism in 1562 promoter nucleotide of collagenase IV with the age and type of metastasis in breast cancer. J Babol Univ Med Sci. 2009; 6(10): 7-13. [in Persian]
[29].Sedaie Bonab A, Pouladi N, Hosseinpourfeizi MA, Ravanbakhsh Gavgani R, Dehghan R, Azarfam P, Montazeri V, Fakhrjou A. Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population. Med Oncol. 2014; 31(9): 168
[30].Pouladi N, Kouhsari SM, Feizi MH, Dehghan R, Azarfam P, Farajzadeh D. Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev. 2014; 15(6) :2631-4.
[31].Dulcie LAI, Visser-Grieve S, Xiaolong YANG. Tumour suppressor genes in chemotherapeutic drug response. Biosci. Rep. 2012; 32: 361-374.
[32].Sax JK, El-Deiry WS. P53 downstream targets and chemosensitivity. Cell Death Differ. 2003; 10: 413-417.
[33].Morgan SE, Kim R, Wang PC et al. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene. 2000; 19(43): 5010-9.
[34].Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999; 104: 263-269.....
)